Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 631

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 631
---
 three months ended September 30, 2025 and 2024, respectively, and $4.6 million and $7.2 million for the nine months ended
September 30, 2025 and 2024, respectively. As of September 30, 2025 and December 31, 2024, Scilex Pharma had ending balances of accrued royalty payables of $3.6 million and $2.2 million, respectively. Total royalty expense
recorded within cost of revenue was $1.9 million and $2.2 million for the three months ended September 30, 2025 and 2024, respectively, and $4.2 million and $6.9 million for the nine months ended September 30, 2025 and
2024, respectively.

Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any
Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with GAAP. If Scilex Pharma were to sublicense
the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until October 2, 2028, the date that is ten years
from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers
terminate it upon six-months’ written notice.

F-101

On February 16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the
“Supply Agreement”) with the Developers to provide commercial supply of ZTlido and SP-103 to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment,
product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product
Development Agreement.

Sales Operations Services

In November 2014, Scilex Pharma entered into a project agreement with a vendor, pursuant to which the vendor has agreed to perform certain services in
accordance with written work orders, which was subsequently superseded by a new project agreement entered into in May 2025